MA45675B1 - Procédés et compositions pour le traitement du cancer - Google Patents

Procédés et compositions pour le traitement du cancer

Info

Publication number
MA45675B1
MA45675B1 MA45675A MA45675A MA45675B1 MA 45675 B1 MA45675 B1 MA 45675B1 MA 45675 A MA45675 A MA 45675A MA 45675 A MA45675 A MA 45675A MA 45675 B1 MA45675 B1 MA 45675B1
Authority
MA
Morocco
Prior art keywords
cancer
treatment
compositions
methods
polypeptide
Prior art date
Application number
MA45675A
Other languages
English (en)
Other versions
MA45675A (fr
Inventor
Laura Soucek
Toni JAUSET GONZÁLEZ
Marie-Eve Beaulieu
Original Assignee
Institució Catalana de Recerca I EstudisAvançats
Fundació Privada Institut D'investigacióoncològica De Vall Hebron
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institució Catalana de Recerca I EstudisAvançats, Fundació Privada Institut D'investigacióoncològica De Vall Hebron filed Critical Institució Catalana de Recerca I EstudisAvançats
Publication of MA45675A publication Critical patent/MA45675A/fr
Publication of MA45675B1 publication Critical patent/MA45675B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6445—Haemoglobin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne un polypeptide comprenant ou constitué du polypeptide de SEQ ID NO: 1 dans laquelle le résidu X à la position 89 de la SEQ ID NO: 1 n'est pas une cystéine, ou un variant fonctionnellement équivalent dudit polypeptide dans lequel le résidu X à la position 89 de SEQ ID NO: 1 n'est pas une cystéine et leur utilisation en médecine, en particulier dans la prévention et/ou le traitement du cancer.
MA45675A 2016-07-15 2017-07-17 Procédés et compositions pour le traitement du cancer MA45675B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16382339.6A EP3269734A1 (fr) 2016-07-15 2016-07-15 Procédés et compositions pour le traitement du cancer
PCT/EP2017/067998 WO2018011433A1 (fr) 2016-07-15 2017-07-17 Méthodes et compositions permettant le traitement du cancer
EP17746413.8A EP3484913B1 (fr) 2016-07-15 2017-07-17 Procédés et compositions pour le traitement du cancer

Publications (2)

Publication Number Publication Date
MA45675A MA45675A (fr) 2021-04-21
MA45675B1 true MA45675B1 (fr) 2024-07-31

Family

ID=56497695

Family Applications (1)

Application Number Title Priority Date Filing Date
MA45675A MA45675B1 (fr) 2016-07-15 2017-07-17 Procédés et compositions pour le traitement du cancer

Country Status (21)

Country Link
US (1) US11427621B2 (fr)
EP (2) EP3269734A1 (fr)
JP (1) JP7090593B2 (fr)
KR (1) KR102232500B1 (fr)
CN (1) CN109563151B (fr)
AU (1) AU2017295071B2 (fr)
BR (1) BR112019000732A2 (fr)
EA (1) EA201990298A1 (fr)
ES (1) ES2985967T3 (fr)
HR (1) HRP20241153T1 (fr)
HU (1) HUE067973T2 (fr)
IL (1) IL264176B2 (fr)
MA (1) MA45675B1 (fr)
MD (1) MD3484913T2 (fr)
MX (1) MX2019000346A (fr)
PL (1) PL3484913T3 (fr)
RS (1) RS65983B1 (fr)
SG (1) SG11201900021PA (fr)
SM (1) SMT202400360T1 (fr)
WO (1) WO2018011433A1 (fr)
ZA (1) ZA201900960B (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101729826B1 (ko) * 2015-01-09 2017-05-11 주식회사 동희산업 플라스틱 연료탱크의 제조방법
KR101862239B1 (ko) * 2016-07-07 2018-05-30 주식회사 동희산업 플라스틱 연료탱크의 제조방법
KR101859583B1 (ko) * 2016-07-07 2018-06-27 주식회사 동희산업 플라스틱 연료탱크의 제조방법
EP3269734A1 (fr) 2016-07-15 2018-01-17 Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron Procédés et compositions pour le traitement du cancer
EP3841114A4 (fr) * 2018-08-20 2022-06-08 Helix Nanotechnologies, Inc. Méthodes et compositions pour l'expression de l'arn d'inhibiteurs de myc
WO2020187998A1 (fr) * 2019-03-19 2020-09-24 Fundació Privada Institut D'investigació Oncològica De Vall Hebron Polythérapie à l'aide d'omomyc et d'un anticorps se liant à pd-1 ou ctla-4 pour le traitement du cancer
TWI829893B (zh) * 2019-03-19 2024-01-21 瓦爾希伯倫私人腫瘤研究基金會 診斷肺癌的方法
KR102922015B1 (ko) * 2019-10-17 2026-02-04 주식회사 나이벡 Fer 티로신 키나아제 결합능이 있는 신규한 펩타이드 및 이의 용도
KR102398339B1 (ko) * 2020-01-09 2022-05-13 이화여자대학교 산학협력단 일산화질소 전달용 융합 펩타이드 및 이의 용도
CN115397843A (zh) * 2020-04-15 2022-11-25 杭州卫本医药科技有限公司 用于筛选药物的靶标多肽和筛选方法
EP4361633A1 (fr) 2022-10-25 2024-05-01 Peptomyc, S.L. Procédé de prédiction de la réponse à un traitement du cancer
EP4446742A1 (fr) 2023-04-14 2024-10-16 Peptomyc, S.L. Procédé d'évaluation ou de surveillance de la réponse à un traitement du cancer
EP4473974A1 (fr) * 2023-06-07 2024-12-11 Peptomyc, S.L. Polythérapie avec omomyc et des inhibiteurs de kras pour le traitement du cancer

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
DE3169595D1 (en) 1980-11-10 1985-05-02 Gersonde Klaus Method of preparing lipid vesicles by ultrasonic treatment, the use of this method and apparatus for its application
DE3374837D1 (en) 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
US4615885A (en) 1983-11-01 1986-10-07 Terumo Kabushiki Kaisha Pharmaceutical composition containing urokinase
EP1251170A3 (fr) 1992-07-17 2002-10-30 Ribozyme Pharmaceuticals, Inc. Procédé et réactif pour le traitement de maladies animales dépendants de NF-kappaB
US6447796B1 (en) 1994-05-16 2002-09-10 The United States Of America As Represented By The Secretary Of The Army Sustained release hydrophobic bioactive PLGA microspheres
JPH11510389A (ja) 1995-07-31 1999-09-14 アメリカ合衆国 細胞タンパク質の機能を不活性化するためのタンパク質−タンパク質相互作用表面の拡張
US6395713B1 (en) 1997-07-23 2002-05-28 Ribozyme Pharmaceuticals, Inc. Compositions for the delivery of negatively charged molecules
EP2138191A1 (fr) 1998-01-05 2009-12-30 University Of Washington Amélioration du transport par l'utilisation d'agents de rupture de membranes
JP2002537828A (ja) 1999-03-10 2002-11-12 フォゲン リミティド 細胞への物質のデリバリー
US20020130430A1 (en) 2000-12-29 2002-09-19 Castor Trevor Percival Methods for making polymer microspheres/nanospheres and encapsulating therapeutic proteins and other products
US20030077829A1 (en) 2001-04-30 2003-04-24 Protiva Biotherapeutics Inc.. Lipid-based formulations
US7060498B1 (en) 2001-11-28 2006-06-13 Genta Salus Llc Polycationic water soluble copolymer and method for transferring polyanionic macromolecules across biological barriers
US7141540B2 (en) 2001-11-30 2006-11-28 Genta Salus Llc Cyclodextrin grafted biocompatible amphilphilic polymer and methods of preparation and use thereof
WO2006135436A2 (fr) 2004-10-22 2006-12-21 University Of Florida Research Foundation, Inc. Inhibition de l'expression genique et ses usages therapeutiques
US9241920B2 (en) * 2011-10-27 2016-01-26 New York University Inhibition of c-Myc ubiquitination to prevent cancer initiation and progression
EP2801370A1 (fr) * 2013-05-07 2014-11-12 Fundació Privada Institut d'Investigació Oncològica de Vall Hebron Procédé et compositions de traitement du cancer
EP3269734A1 (fr) 2016-07-15 2018-01-17 Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron Procédés et compositions pour le traitement du cancer

Also Published As

Publication number Publication date
AU2017295071B2 (en) 2022-06-09
CA3029781A1 (fr) 2018-01-18
US11427621B2 (en) 2022-08-30
EP3484913B1 (fr) 2024-07-03
EP3269734A1 (fr) 2018-01-17
HRP20241153T1 (hr) 2024-11-22
IL264176B1 (en) 2023-03-01
US20200247857A1 (en) 2020-08-06
AU2017295071A1 (en) 2019-01-31
BR112019000732A2 (pt) 2019-07-30
EA201990298A1 (ru) 2019-06-28
KR20190032427A (ko) 2019-03-27
WO2018011433A1 (fr) 2018-01-18
EP3484913C0 (fr) 2024-07-03
MX2019000346A (es) 2019-04-01
KR102232500B1 (ko) 2021-03-26
CN109563151B (zh) 2023-03-07
SMT202400360T1 (it) 2024-11-15
RS65983B1 (sr) 2024-10-31
JP7090593B2 (ja) 2022-06-24
ZA201900960B (en) 2020-05-27
SG11201900021PA (en) 2019-01-30
CN109563151A (zh) 2019-04-02
PL3484913T3 (pl) 2025-01-07
IL264176A (en) 2019-02-28
MA45675A (fr) 2021-04-21
EP3484913A1 (fr) 2019-05-22
HUE067973T2 (hu) 2024-11-28
IL264176B2 (en) 2023-07-01
MD3484913T2 (ro) 2024-10-31
JP2019525753A (ja) 2019-09-12
ES2985967T3 (es) 2024-11-08

Similar Documents

Publication Publication Date Title
EA201990298A1 (ru) Способы и композиции для лечения рака
PH12020551019A1 (en) IL-22 Fc FUSION PROTEINS AND METHODS OF USE
ZA201803396B (en) Anti-n3pglu amyloid beta peptide antibodies and uses thereof
MA47688A (fr) Compositions utiles dans le traitement de l'amyotrophie spinale
GEP20257840B (en) Tyk2 pseudokinase ligands
NZ739392A (en) Methods for treating hepcidin-mediated disorders
MX378431B (es) Uso terapèutico de proteìnas morfogenèticas òseas.
MA39342B2 (fr) Anticorps il -21
PH12018502465A1 (en) Mic-1 compounds and use thereof
PH12019550241A1 (en) Mic-1 compounds and uses thereof
EP3638298A4 (fr) Immunogènes peptidiques provenant de l'extrémité c-terminale d'une protéine, l'alpha-synucléine, et compositions en contenant pour le traitement des synucléinopathies
MA46548B1 (fr) Fsh pour le traitement de l'infertilité
EP4623925A3 (fr) Compositions peptidiques et procédés d'utilisation
WO2015171558A3 (fr) Benzènesulfonamido et composés apparentés utilisés en tant qu'agonistes de rorγ et pour le traitement de maladie
MX2019003805A (es) Activadores de flujo autofágico y fosfolipasa d y depuración de acumulaciones de proteína que incluyen tau y tratamiento de proteinopatías.
JP2017505772A5 (fr)
CL2018001343A1 (es) Lactoferrina para uso en el diagnóstico o el pronóstico de la enfermedad de alzheimer o en el diagnóstico de la enfermedad de parkinson
EP4279132A3 (fr) Dosage nocturne chronique de lasmiditan pour la prévention de la migraine
PH12021550122A1 (en) Solubilized apyrases, methods and use
MX2021010766A (es) Anticuerpos que se unen a la proteína del gen 6 inducible por el factor de necrosis tumoral (tsg-6) y usos de estos.
EP3530278A4 (fr) Composition comprenant un peptide inhibiteur de protéine phosphatase 1 pour le traitement des maladies vasculaires
EA202190096A1 (ru) Композиция, содержащая аналог соматостатина, для радиофармацевтического применения
MA55507A (fr) Macitentan destiné à être utilisé dans le traitement de l'hypertension portopulmonaire
MA39319A1 (fr) Inhibiteur de la protéine de transfert d'ester de cholestéryle (cetp) et compositions pharmaceutiques comprenant ledit inhibiteur pour leur utilisation dans le traitement ou la prévention de maladies cardiovasculaires
FR3047414B1 (fr) Composition pour l'aero-polissage